
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Guangzhou records a whopping growth of over 50%

June 4, 2013 | Analysis | By BioSpectrum Bureau



12a-biospectrum-asia-top-20-survey-rank-12-guangzhou-pharmaceutical-china-profile

Clocking $1.3 billion revenue in 2012, Guangzhou Pharmaceutical recorded a growth of over 50 percent. A well-recognized name in China, Guangzhou Pharmaceutical Holdings is principally engaged in a combination of scientific research and production of pharmaceuticals and traditional Chinese medicines.

The company has invested heavily on technological innovation system, has launched post-doctoral research programmes and has its own R&D center for key pharmaceutical projects.

In 2012, Guangzhou Pharmaceutical proactively adapted to new medical reform policies of the state and was successful in gaining license of tradename "Baiyunshan" for its eight subsidiaries to leverage on market opportunities existing outside Guangdong province and expand its marketshare.

Guangzhou also made initiatives to accelerate the development of China's health industry by increasing its production capacity through newly formed strategic cooperation with raw material providers and packaging material suppliers such as Uni-President and Yinlu. In 2012, the company smoothly carried out progress of clinical research of the therapeutic dual, plasmid HBV DNA vaccine.

It launched products such as no sugar, low sugar and instantly drinkable herbal tea beverages. Guangzhou Pharmaceutical's herbal tea, under brand name An Gong Niu Huang Wan, Zi Shen Yu, Tai Wan, Shu Jin Jian Yao Wan, An Shen Bu Lao Ye, and Xin Xue Dan series, recorded greater increase in sales revenue in 2012. The company applied for 21 invention patents and obtained 17 approvals in China.

The year 2012 was marked by several accolades and recognition for Guangzhou Pharmaceutical. Abiding to high manufacturing practices, the company's National Engineering Research Center of Chinese Medicine Modernization of Extraction and Separation Process was awarded National Engineering Research Center with Excellent Achievement by

National Development and Reform Commission.

Its subsidiaries Zhong Yi, Guangzhou Wang Lao Ji Pharmaceutical, Jing Xiu Tang, Pan Gao Shou and Qi Xing were recognized as Guangzhou demonstration enterprise for the transformation and upgrading of traditional manufacturing industry with advantages by guangzhou economic and trade commission.

The company believes that 2013 will be a critical year for the group as the implementation of China's Twelfth Five-Year Plan will help it to inherit from the past and forge ahead into the future, which can be expected to be full of challenges and opportunities.